JPH11206876A - Filter for leucocyte separation - Google Patents
Filter for leucocyte separationInfo
- Publication number
- JPH11206876A JPH11206876A JP10016782A JP1678298A JPH11206876A JP H11206876 A JPH11206876 A JP H11206876A JP 10016782 A JP10016782 A JP 10016782A JP 1678298 A JP1678298 A JP 1678298A JP H11206876 A JPH11206876 A JP H11206876A
- Authority
- JP
- Japan
- Prior art keywords
- cationization
- degree
- porous substrate
- substrate layer
- quaternary ammonium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000926 separation method Methods 0.000 title claims abstract description 11
- 239000000758 substrate Substances 0.000 claims abstract description 44
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 20
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 4
- 230000017531 blood circulation Effects 0.000 claims abstract description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 9
- 239000004952 Polyamide Substances 0.000 claims description 6
- 229920002647 polyamide Polymers 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- 229920002635 polyurethane Polymers 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- -1 polyethylene Polymers 0.000 claims description 5
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 claims description 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 239000004695 Polyether sulfone Substances 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 229920002492 poly(sulfone) Polymers 0.000 claims description 2
- 229920006393 polyether sulfone Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 description 23
- 238000000034 method Methods 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000000306 component Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229920001410 Microfiber Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- UBMGRWRKCJIKMQ-UHFFFAOYSA-M dodecyl-dimethyl-(3-trimethoxysilylpropyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CCC[Si](OC)(OC)OC UBMGRWRKCJIKMQ-UHFFFAOYSA-M 0.000 description 1
- HSTNMAHVBABHLU-UHFFFAOYSA-M dodecyl-dimethyl-propylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CCC HSTNMAHVBABHLU-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Filtering Materials (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は白血球と血小板に対して
良好な捕捉能を有し、かつ詰まり防止効果に優れた白血
球分離用フィルターに関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a filter for separating leukocytes which has a good ability to trap leukocytes and platelets and has an excellent clogging prevention effect.
【0002】[0002]
【従来の技術】輸血の形態が従来の全血輸血から、患者
が必要としている成分のみを輸血する成分輸血へと変化
して久しいが、この成分輸血においては、分画した血液
成分の純度をいかに高くするかが課題である。2. Description of the Related Art The form of blood transfusion has been changing for a long time from conventional whole blood transfusion to component transfusion for transfusing only the components required by the patient, but in this component transfusion, the purity of the fractionated blood components is reduced. The challenge is how to raise the price.
【0003】なかでも濃厚赤血球(CRC)の場合に
は、白血球や血小板に対する抗体の産生を抑制し、輸血
副作用を予防するために、白血球だけでなく血小板をも
取り除いた純度の高い赤血球であることが良いことは言
うまでもない。[0003] Among them, in the case of concentrated red blood cells (CRC), high-purity red blood cells from which not only white blood cells but also platelets have been removed in order to suppress the production of antibodies against white blood cells and platelets and prevent transfusion side effects. Needless to say, is good.
【0004】このために多くの工夫がなされており、血
球の比重差を利用した重力遠心分離法、血球の粘着およ
び/または付着の作用を利用したフィルター法等があ
る。Many attempts have been made to achieve this, such as a gravity centrifugation method utilizing the specific gravity difference of blood cells, and a filter method utilizing the action of adhesion and / or adhesion of blood cells.
【0005】なかでも、フィルター法は白血球除去効率
の良さ、手技の簡便さなどから広く用いられており、フ
ィルター部分の構造としては極細繊維をカラム内に詰め
たもの、不織布等に2次加工したもの、スポンジ状の3
次元網目状連続多孔体などがその代表例である。[0005] Among them, the filter method is widely used because of its high leukocyte removal efficiency and simplicity of the procedure, and the structure of the filter portion is formed by packing ultra-fine fibers in a column or secondary processing into a nonwoven fabric or the like. Stuff, sponge-like 3
A typical example thereof is a continuous porous body having a three-dimensional network.
【0006】ところで、そのフィルター法によって濃厚
赤血球から白血球と血小板を除去するためには工夫が必
要である。In order to remove white blood cells and platelets from concentrated red blood cells by the filter method, some contrivance is required.
【0007】すなわち、白血球の分離能はフィルターの
孔径を小さくすることで高められることは当然である
が、血小板を除去できるほどの孔径になると、捕捉され
た血球により目詰まりが発生しやすくなってくるので、
孔径の比較的大きなフィルターを用いつつ白血球と血小
板の両方を除去できることが要件となる。[0007] That is, it is natural that the separation ability of leukocytes can be enhanced by reducing the pore size of the filter. However, if the pore size is such that platelets can be removed, clogging is likely to occur due to captured blood cells. Because
A requirement is that both white blood cells and platelets can be removed while using a filter having a relatively large pore size.
【0008】その解決策としてはフィルター基材の表面
部のゼータ電位を正(プラス)にする方法であり、具体
的にはカチオン性の基、すなわち第4級アンモニウム塩
を該基材の表面部に固定するのが良いことが知られてお
り、これによって血小板が基材に吸着(付着)しやすく
なり、除去される。A solution is to make the zeta potential of the surface of the filter substrate positive (positive). Specifically, a cationic group, that is, a quaternary ammonium salt is added to the surface of the substrate. It is known that the platelets are preferably fixed to the substrate, whereby platelets are easily adsorbed (adhered) to the substrate and are removed.
【0009】しかしながら、このような方法の場合、基
材のカチオン化の度合い(カチオン化度)によって血小
板の吸着能が変化してしまうことや血液には個体差が有
るため血小板の吸着挙動が多様であること等に起因する
問題が生じる。However, in the case of such a method, the platelet adsorption ability varies depending on the degree of cationization of the base material (degree of cationization) and the platelet adsorption behavior varies due to individual differences in blood. This causes a problem due to the above.
【0010】カチオン化度が高ければ血小板が吸着しや
すくなり、除去も促進されるのであるが血小板が高濃度
のままカチオン化度の高い基材に触れると、その部分に
血小板が集中して吸着され基材の孔が小さくなり流速が
低下する傾向にあり、極端な場合としては目詰まりが発
生しフィルターとしての機能を果たさなくなる。[0010] If the degree of cationization is high, platelets are more likely to be adsorbed and removal is promoted. However, if the platelet is in a high concentration and touches a substrate with a high degree of cationization, platelets concentrate on that part and are adsorbed. As a result, the pores of the base material tend to be small, and the flow velocity tends to decrease. In an extreme case, clogging occurs, and the function as a filter cannot be achieved.
【0011】逆の場合としてカチオン化度が低ければ血
小板の吸着が不十分となる。On the contrary, when the degree of cationization is low, the adsorption of platelets becomes insufficient.
【0012】[0012]
【発明が解決しようとする課題】本発明は、白血球およ
び血小板の除去を目的としたフィルターに関わる上記の
ごとき問題点を解決すべくなされたものであり、良好な
除去性能を有しかつ目詰まりしにくいフィルターを提供
することを目的とする。SUMMARY OF THE INVENTION The present invention has been made in order to solve the above-mentioned problems relating to a filter for removing leukocytes and platelets, and has a good removing performance and is clogged. It is intended to provide a filter that is difficult to perform.
【0013】[0013]
【課題を解決するための手段】本発明の第1は表面固定
された第4級アンモニウム塩の濃度が異なる少なくとも
3種類以上の多孔性基材から構成されたフィルターであ
って、下流側に向けて第4級アンモニウム塩濃度が高め
られていることを特徴とする白血球分離用フィルターで
ある。A first aspect of the present invention is a filter comprising at least three or more types of porous substrates having different concentrations of quaternary ammonium salts immobilized on a surface thereof, the filter being directed downstream. Wherein the quaternary ammonium salt concentration is increased.
【0014】また本発明の多孔性基材の好ましい組み合
わせとしてはカチオン化度が実質的にゼロの第1の多
孔性基材部、カチオン化度が0.2〜0.5の多孔性
基材部、カチオン化度が0.6〜1.0でかつ部よ
り0.2〜0.6高い第3の多孔性基材部からなる白血
球分離用フィルターである。The preferred combinations of the porous substrates of the present invention include a first porous substrate portion having a cationization degree of substantially zero, and a porous substrate having a cationization degree of 0.2 to 0.5. And a third porous substrate having a cationization degree of 0.6 to 1.0 and a 0.2 to 0.6 higher than the part.
【0015】更に上述の多孔性基材の組み合わせが血液
流路の上流側より、、の順に配置されてなる事が
好ましく、このような構成とすることにより、良好な白
血球除去率と血小板除去率が維持されつつ実用的な流速
が安定して得られる。Further, it is preferable that the combination of the above-mentioned porous substrates is arranged in the order of from the upstream side of the blood flow path. With such a configuration, a good leukocyte removal rate and a good platelet removal rate are obtained. , And a practical flow rate can be stably obtained.
【0016】本発明において用いられる多孔性基材とし
てはポリエチレン、ポリプロピレン、ポリウレタン、ポ
リエステル、ポリアミド、ポリスルホン、ポリエーテル
スルホン、ポリアミドポリエーテルブロックコポリマ
ー、ポリエステルポリエーテルブロックコポリマー、エ
チレンビニルアルコールコポリマーなどフィルターとし
て用いられ得るポリマーからなり、形状としては多孔質
体、平膜、不織布、織布、編布もしくはそれらのコンポ
ジットなどが挙げられる。As the porous substrate used in the present invention, polyethylene, polypropylene, polyurethane, polyester, polyamide, polysulfone, polyethersulfone, polyamide polyether block copolymer, polyester polyether block copolymer, ethylene vinyl alcohol copolymer and the like are used as filters. And a porous body, a flat membrane, a nonwoven fabric, a woven fabric, a knitted fabric or a composite thereof.
【0017】特に好ましい有機ポリマーはポリウレタ
ン、ポリエステル、ポリアミドあるいはエチレンビニル
アルコールコポリマーであり、形状としては3次元網目
状多孔体もしくは不織布が良い。Particularly preferred organic polymers are polyurethane, polyester, polyamide or ethylene vinyl alcohol copolymer, and the shape is preferably a three-dimensional network porous body or nonwoven fabric.
【0018】また白血球や血小板もしくは除去率および
濾過時の流速を考慮すると、最頻孔径が1〜7ミクロ
ン、より好ましくは2〜6ミクロンであるフィルターで
あるのが良い。In consideration of the leukocyte or platelet removal rate and the flow rate at the time of filtration, a filter having a most frequent pore diameter of 1 to 7 microns, more preferably 2 to 6 microns is preferred.
【0019】次に本発明における「表面固定された第4
級アンモニウム塩」とは上記多孔性基材に化学結合の形
であるいはコートの形で固定された第4級アンモニウム
塩を意味し、例えば以下の方法で固定される。Next, in the present invention, "the surface-fixed fourth
The term "quaternary ammonium salt" means a quaternary ammonium salt fixed to the porous substrate in the form of a chemical bond or a coat, and is fixed by, for example, the following method.
【0020】多孔性基材の表面に、プラズマ開始重合
によって少なくとも1種の官能基(酸ハライド基、イソ
シアネート基、エポキシ基等)を導入しこれらの官能基
と反応可能な部位(アミノ基、カルボキシル基、ヒドロ
キシル基等)を有する第4級アンモニウム塩化合物を結
合させる方法。代表例としてはグリシジルアクリレート
を表面グラフト重合(エポキシ基が導入される)し、次
いで下記一般式(1)At least one type of functional group (acid halide group, isocyanate group, epoxy group, etc.) is introduced into the surface of the porous substrate by plasma-initiated polymerization, and a site capable of reacting with these functional groups (amino group, carboxyl group, etc.). A quaternary ammonium salt compound having a hydroxyl group or a hydroxyl group). As a typical example, glycidyl acrylate is subjected to surface graft polymerization (in which an epoxy group is introduced), and then the following general formula (1)
【0021】[0021]
【化学式1】 [Chemical formula 1]
【0022】の化合物と反応させる方法がある。There is a method of reacting with the compound of the formula (1).
【0023】オルガノシリコーンタイプの第4級アン
モニウム塩を多孔性基材の表面に固定する方法。代表例
としては下記一般式(2)A method of fixing a quaternary ammonium salt of an organosilicone type to the surface of a porous substrate. A typical example is the following general formula (2)
【0024】[0024]
【化学式2】 [Chemical formula 2]
【0025】と硫酸塩界面活性剤(例えばラウリル硫酸
ナトリウム)とを含む水溶液で、多孔性基材を処理する
方法がある。There is a method in which a porous substrate is treated with an aqueous solution containing a sulfate surfactant (for example, sodium lauryl sulfate).
【0026】冒頭に述べたごとく、本発明の白血球分離
用フィルターは、表面固定された第4級アンモニウム塩
が異なる少なくとも3種類以上の多孔性基材から構成さ
れている。As described at the outset, the leukocyte separation filter of the present invention is composed of at least three or more types of porous substrates having different quaternary ammonium salts fixed on the surface.
【0027】ここで種類とは必ずしも枚数を意味しな
い。本発明の趣旨は第4級アンモニウム塩の濃度により
カチオン化度の異なる少なくとも3種類以上言い換えれ
ば3層以上からなる構成である。Here, the type does not necessarily mean the number of sheets. The gist of the present invention is a constitution comprising at least three or more types having different degrees of cationization depending on the concentration of the quaternary ammonium salt, in other words, three or more layers.
【0028】例えばポリウレタン性多孔質シート6枚よ
りなるフィルターであってそのシートが2枚づつの3層
からなる、あるいは1枚から構成される第1層、2枚か
ら構成される第2層および3枚から構成される第3層か
らなるというように、異なった第4級アンモニウム塩の
濃度を有している層が少なくとも3種類以上より構成さ
れている物で有れば本発明の趣旨に合致するものであ
り、その各層における枚数の組み合わせは容積、濾過量
等のからみにより任意に構成されるものであり何ら限定
される物ではない。For example, a filter composed of six polyurethane porous sheets, wherein the sheet is composed of three layers of two sheets, or a first layer composed of one sheet, a second layer composed of two sheets, and If the layer having different quaternary ammonium salt concentrations is composed of at least three or more types, such as a third layer composed of three sheets, the present invention is not limited to the above. The combination of the number of sheets in each layer is arbitrarily configured in view of the volume, the amount of filtration, and the like, and is not limited at all.
【0029】また第4級アンモニウム塩の濃度の種類は
実用性を考えると5種類以下が好ましい。The number of quaternary ammonium salts is preferably 5 or less in consideration of practicality.
【0030】[0030]
【実施例】以下に実施例により本発明をさらに具体的に
説明するが本発明はその効果を有する実施態様であれば
これらになんら限定されるものではない。EXAMPLES The present invention will be described in more detail with reference to the following Examples, but it should not be construed that the present invention is limited to these embodiments as long as the embodiments have the effects.
【0031】1−1.実験方法(実施例1〜4、比較例
1〜8) フィルター基材のカチオン化処理:最頻孔径3μm、
空孔率90%、厚さ1.3mmのポリウレタン製の3次
元網目状連続多孔膜(20cm幅×100cm長)を、
3−(トリメトキシシリル)プロピルジメチル−ラウリ
ルアンモニウムクロライド(A)(分子量412)とラ
ウリル硫酸ナトリウム(B)(分子量288)とを含む
水溶液8Lに浸漬し50℃×60分の条件で処理した。
次いで70℃の純水で湯煎後、絞り、70℃×12時間
の条件で乾燥した。1-1. Experimental Method (Examples 1 to 4, Comparative Examples 1 to 8) Cationization treatment of filter base material: mode diameter 3 μm,
A polyurethane three-dimensional mesh-like continuous porous membrane (20 cm wide × 100 cm long) having a porosity of 90% and a thickness of 1.3 mm is
It was immersed in 8 L of an aqueous solution containing 3- (trimethoxysilyl) propyldimethyl-lauryl ammonium chloride (A) (molecular weight: 412) and sodium lauryl sulfate (B) (molecular weight: 288), and treated at 50 ° C. for 60 minutes.
Next, the product was immersed in pure water at 70 ° C., squeezed, and dried at 70 ° C. for 12 hours.
【0032】プロピルジメチル−ラウリルアンモニウ
ムクロライド(A)もしくはラウリル硫酸ナトリウム
(B)の濃度を変えて上記の操作を行い表1に示すカ
チオン化度の異なる基材を作製した。The above operations were carried out by changing the concentration of propyldimethyl-lauryl ammonium chloride (A) or sodium lauryl sulfate (B) to produce substrates having different degrees of cationization as shown in Table 1.
【0033】[0033]
【表1】 [Table 1]
【0034】フィルター基材のカチオン化度(第4級
アンモニウム塩の固着量)の測定:の処理後のポリウ
レタン膜から2cm径の小片をサンプリングし、以下の
方法に基づいてカチオン化度を測定した。Measurement of the degree of cationization of the filter substrate (the amount of quaternary ammonium salt fixed): A small sample of 2 cm in diameter was sampled from the polyurethane film after the treatment, and the degree of cationization was measured based on the following method. .
【0035】なお作業手順(a)から(c)は室温で処
理を行う。The procedures (a) to (c) are performed at room temperature.
【0036】(a)多孔性基材をリン酸緩衝液に浸漬す
る。(A) Immerse the porous substrate in a phosphate buffer.
【0037】(b)浸漬後の基材を0.025mMトリ
パンブルー/リン酸緩衝液中で15分間浸漬処理する。(B) The immersed substrate is immersed in a 0.025 mM trypan blue / phosphate buffer for 15 minutes.
【0038】(c)(b)の処理後の基材を再度リン酸
緩衝液に10分間漬ける。(C) The substrate after the treatment of (b) is immersed again in a phosphate buffer for 10 minutes.
【0039】(d)浸漬後の基材を60℃で1時間乾燥
し、基材表面の反射吸光度を波長550〜600nMの
範囲で測定する。(D) The substrate after immersion is dried at 60 ° C. for 1 hour, and the reflection absorbance of the substrate surface is measured in the wavelength range of 550 to 600 nM.
【0040】血液濾過性能の評価:第1表のC0〜C4
の基材(膜)から直径6cmの円形片を打ち抜き、この
基材片を適宜選択し3枚を重ね、専用のモジュールに充
填した。このモジュールに400ML採血をして得られ
たCPD加ヒト赤血球濃厚液(CRC)1単位を流し
た。濾過処理前後のCRC中の血球数を自動血球算定装
置(Sysmex NE−6000、東亜医用電子
(株)製)とフローサイトメーター(Cyto−ACE
150、日本分光(株)製)を用いて算定の後、液量に
基づいて各血球成分の絶対数を求め、これより白血球の
除去率、血小板の除去率および赤血球の回収率を求め
た。Evaluation of hemofiltration performance: C 0 to C 4 in Table 1
A circular piece having a diameter of 6 cm was punched out from the substrate (film), and the substrate pieces were appropriately selected, three sheets were stacked, and filled in a dedicated module. One unit of CPD-added human erythrocyte concentrate (CRC) obtained by collecting 400 ML blood was passed through this module. The number of blood cells in the CRC before and after the filtration treatment is determined by an automatic blood cell counting device (Sysmex NE-6000, manufactured by Toa Medical Electronics Co., Ltd.) and a flow cytometer (Cyto-ACE).
150, manufactured by JASCO Corporation, the absolute number of each blood cell component was determined based on the volume of the liquid, and the leukocyte removal rate, platelet removal rate, and red blood cell recovery rate were determined from this.
【0041】1−2.実験結果 (1)目詰まりを起こしやすい濃厚赤血球(CRC)を
濾過原液とし表1に記載の基材を用いて組み合わせた組
み合わせおよび濾過結果を表2に示す。1-2. Experimental Results (1) Table 2 shows the combinations of concentrated red blood cells (CRC), which easily cause clogging, as the undiluted filtration solution using the substrates shown in Table 1, and the results of filtration.
【0042】[0042]
【表2】 [Table 2]
【0043】(2)血小板を捕捉しにくい濃厚赤血球
(CRC)を濾過原液とし表1に記載の基材を用いて組
み合わせた組み合わせおよび濾過結果を表3に示す。(2) Table 3 shows the combinations of concentrated red blood cells (CRC) that are difficult to capture platelets as the undiluted filtration solution using the base materials shown in Table 1 and the results of filtration.
【0044】[0044]
【表3】 [Table 3]
【0045】第2表および第3表より明らかなように、 第4級アンモニウム塩の存在で白血球除去率および血
小板除去率は向上するがカチオン化度の高い膜のみでは
フィルターの目詰まりが発生しやすく、カチオン化度の
低い膜のみでは白血球除去率および血小板除去率が不十
分である、 カチオン化度の低い膜と高い膜とを組み合わせかつカ
チオン化度の低い膜側から高い膜側へと濃厚赤血球を流
すことにより濃厚赤血球の種類に関わらず実用的な流速
が安定して保たれかつ良好な除去性能が得られる、 少なくとも3種類以上配置することによりカチオン化
度が異なる2種の組み合わせより適用される血液の種類
に関わらず濾過時間、白血球除去率および血小板除去率
のバランスに優れている、ことが確認される。As is clear from Tables 2 and 3, the presence of the quaternary ammonium salt improves the leukocyte removal rate and the platelet removal rate, but the filter having a high degree of cationization only causes clogging of the filter. Easy to use, low leukocyte removal rate and platelet depletion rate are insufficient with only low cationization membrane. Combination of low cationization membrane and high cationization membrane and thickening from low cationization membrane side to high cationization membrane side By flowing red blood cells, a practical flow rate can be stably maintained regardless of the type of dense red blood cells, and good removal performance can be obtained. By applying at least three or more types, it can be applied from a combination of two types with different degrees of cationization It is confirmed that the filtration time, the leukocyte removal rate and the platelet removal rate are excellent in balance regardless of the type of blood to be used.
【0046】[0046]
【発明の効果】以上詳述したごとく、本発明は表面に固
定された第4級アンモニウム塩の濃度が異なる少なくと
も3種類以上の多孔性基材を上流側から下流側に向けて
第4級アンモニウム塩の濃度が高まるように配置された
構成からなる白血球除去フィルターであり、安定した流
速と良好な白血球および血小板除去性能を有するので医
療への大きな貢献が期待できる。As described above in detail, the present invention provides at least three or more kinds of porous base materials having different concentrations of quaternary ammonium salts fixed to the surface by moving quaternary ammonium salts from the upstream side to the downstream side. It is a leukocyte removal filter having a configuration arranged to increase the concentration of salt, and has a stable flow rate and good leukocyte and platelet removal performance, so that a great contribution to medical treatment can be expected.
Claims (7)
度が異なる少なくとも3種類以上の多孔性基材から構成
されたフィルターであって、下流側に向けて第4級アン
モニウム塩濃度が高められていることを特徴とする白血
球分離用フィルター。1. A filter comprising at least three or more types of porous substrates having different concentrations of quaternary ammonium salts fixed on the surface, wherein the concentration of the quaternary ammonium salts is increased toward the downstream side. A leukocyte separation filter characterized by the following:
ロの多孔性基材層、カチオン化度が0.2〜0.5の
多孔性基材層および、カチオン化度が0.6〜1.0
でかつより0.2〜0.6高い多孔性基材層からなる
ことを特徴とする請求項1記載の白血球分離用フィルタ
ー。2. The base material layer according to claim 1, wherein said base material layer has a cationization degree of substantially zero, a cationization degree of 0.2 to 0.5, and a cationization degree of 0.2 to 0.5. 6-1.0
The leukocyte separation filter according to claim 1, comprising a porous substrate layer which is 0.2 to 0.6 higher in thickness.
ン化度が実質的にゼロの多孔性基材層、カチオン化度
が0.2〜0.5の多孔性基材層および、カチオン化
度が0.6〜1.0でかつより0.2〜0.6高い多
孔性基材層の順に配されてなることを特徴とする請求項
1記載の白血球分離用フィルター。3. The porous substrate layer wherein the degree of cationization is substantially zero from the upstream side of the blood flow path, the porous substrate layer having a degree of cationization of 0.2 to 0.5, and The leukocyte separation filter according to claim 1, wherein the porous substrate layer has a degree of cationization of 0.6 to 1.0 and 0.2 to 0.6 higher.
ン、ポリウレタン、ポリエステル、ポリアミド、ポリス
ルホン、ポリエーテルスルホン、ポリアミドポリエーテ
ルブロックコポリマー、ポリエステルポリエーテルブロ
ックコポリマー、エチレンビニルアルコールコポリマー
などフィルターとして用いられるポリマーの群から選択
されてなることを特徴とする請求項1に記載の白血球分
離用フィルター。4. The base material is a group of polymers such as polyethylene, polypropylene, polyurethane, polyester, polyamide, polysulfone, polyethersulfone, polyamide polyether block copolymer, polyester polyether block copolymer, and ethylene vinyl alcohol copolymer. The white blood cell separation filter according to claim 1, wherein the filter is selected from the group consisting of:
ル、ポリアミドあるいは、エチレンビニルアルコールコ
ポリマーの有機ポリマーから選択されてなる請求項1に
記載の白血球分離用フィルター。5. The leukocyte separation filter according to claim 1, wherein the substrate is selected from polyurethane, polyester, polyamide, and an organic polymer of ethylene vinyl alcohol copolymer.
とを特徴とする請求項1に記載の白血球分離用フィルタ
ー。6. The leukocyte separation filter according to claim 1, wherein the most frequent pore diameter of the substrate is 1 to 7 μm.
とを特徴とする請求項1に記載の白血球分離用フィルタ
ー。7. The leukocyte separation filter according to claim 1, wherein the mode diameter of the base material is 2 to 5 μm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10016782A JPH11206876A (en) | 1998-01-29 | 1998-01-29 | Filter for leucocyte separation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10016782A JPH11206876A (en) | 1998-01-29 | 1998-01-29 | Filter for leucocyte separation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH11206876A true JPH11206876A (en) | 1999-08-03 |
Family
ID=11925769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10016782A Pending JPH11206876A (en) | 1998-01-29 | 1998-01-29 | Filter for leucocyte separation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH11206876A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001032236A1 (en) * | 1999-11-01 | 2001-05-10 | Asahi Medical Co., Ltd. | Filter for selectively removing leukocyte |
| WO2002060557A1 (en) * | 2001-01-29 | 2002-08-08 | Asahi Medical Co., Ltd. | Filter for processing blood and process for producing the same |
| JP2010234079A (en) * | 2003-07-03 | 2010-10-21 | Fresenius Hemocare Italia Srl | Filter for removal of substances from blood products |
-
1998
- 1998-01-29 JP JP10016782A patent/JPH11206876A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001032236A1 (en) * | 1999-11-01 | 2001-05-10 | Asahi Medical Co., Ltd. | Filter for selectively removing leukocyte |
| US6977044B1 (en) | 1999-11-01 | 2005-12-20 | Asahi Medical Co., Ltd. | Filter for selectively removing leukocytes |
| CN100342927C (en) * | 1999-11-01 | 2007-10-17 | 旭化成医疗株式会社 | Filters for selective removal of white blood cells |
| WO2002060557A1 (en) * | 2001-01-29 | 2002-08-08 | Asahi Medical Co., Ltd. | Filter for processing blood and process for producing the same |
| AU2002228363B2 (en) * | 2001-01-29 | 2006-03-16 | Asahi Kasei Medical Co., Ltd | Filter for processing blood and process for producing the same |
| US7156240B2 (en) * | 2001-01-29 | 2007-01-02 | Asahi Kasei Medical Co., Ltd. | Filter for processing blood and process for producing the same |
| KR100771778B1 (en) * | 2001-01-29 | 2007-10-30 | 아사히 카세이 메디칼 가부시키가이샤 | Filter for blood treatment and manufacturing method thereof |
| JP2010234079A (en) * | 2003-07-03 | 2010-10-21 | Fresenius Hemocare Italia Srl | Filter for removal of substances from blood products |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3311091B2 (en) | Filter for separating white blood cells and filter for separating white blood cells and platelets | |
| JP4587213B2 (en) | Biocompatible polymer and leukocyte selective removal filter material using the same | |
| JP4404468B2 (en) | Blood filter and manufacturing method thereof | |
| US5498336A (en) | Leukocyte-removing filter and leukocyte-removing apparatus furnished therewith | |
| US7156240B2 (en) | Filter for processing blood and process for producing the same | |
| ES2795675T3 (en) | Leukocyte filtration unit with reduced platelet adhesion | |
| JP4271265B2 (en) | Leukocyte removal filter material | |
| JPH03173825A (en) | Filter for purifying blood platelet | |
| EP0554460A1 (en) | Filter medium for selective removal of leukocytes and device packed therewith | |
| WO1987005812A1 (en) | Filter medium for selectively removing leucocytes | |
| JPWO1999011304A1 (en) | Leukocyte removal filter material | |
| US7410066B2 (en) | Filter for selectively eliminating leukocytes | |
| US20030146150A1 (en) | Novel leukapheretic filter | |
| JPH11206876A (en) | Filter for leucocyte separation | |
| JPH11267199A (en) | Blood treatment method and device | |
| CN104923091B (en) | Leukocyte filtration membrane, method for producing same, and use thereof | |
| Deppisch et al. | Biocompatibility of the polyamide membranes | |
| JP3459836B2 (en) | Platelet purification filter | |
| JP4393218B2 (en) | Virus removal blood processing apparatus and virus removal method | |
| JPH10328295A (en) | White blood cell separating filter and manufacture therefor | |
| JP3301443B2 (en) | Leukocyte and platelet removal filter | |
| CN201036634Y (en) | White blood cell platelet removing filtering device and using white blood cell removing filtering component | |
| JP4284436B2 (en) | Method for producing leukocyte removal filter material and filter material | |
| JP2001347116A (en) | White blood cell removing filter device | |
| JP2001046844A (en) | Filter for selectively removing white blood corpuscle and coating liquid therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20041007 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041019 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041207 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050412 |